Recent Posts

Just published…With ~50% patients not requiring additional treatment for 9 mon…

Just published…With ~50% patients not requiring additional treatment for 9 months after the last CLS-TA treatment, demonstrates the potential for durability with the suprachoroidal platform & small molecule suspensions such as CLS-TA. #retina #eyes https://t.co/JRiSW8r5ht Source by Thomas Ciulla, MD, MBA Return to main website.

Looking forward to participating in this week’s Wet AMD & DME Drug Development S…

Looking forward to participating in this week’s Wet AMD & DME Drug Development Summit: #eyes #ophthalmology #retina #macula #diabetes #diabeticretinopathy #AMD #maculardegeneration #drugdevelopment #healthcare #biotech #biotechnology #clinicalresearch https://t.co/z903ngBrXO Source by Thomas Ciulla, MD, MBA Return to main website.

Given recent clinical trial results, there has been great interest in our review…


Given recent clinical trial results, there has been great interest in our review of this pathway for the treatment of macular degeneration and diabetic macular edema …https://t.co/OaBS7cUlXs


Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @ThomasCiullaMD: Just published: OCT plays a key role in retina care & clinic…

RT @ThomasCiullaMD: Just published: OCT plays a key role in retina care & clinical trials, but OCT biomarkers can show limited correlation… Source by Thomas Ciulla, MD, MBA Return to main website.

Recently published: The AZALEA trial further supports suprachoroidal delivery f…

Recently published: https://t.co/zXdrj69jwc The AZALEA trial further supports suprachoroidal delivery for retinal disorders… #retina #eyes #ophthalmology #suprachoroidal #macula #clinicaltrials #clinicalresearch https://t.co/srVNk3jgpX Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ThomasCiullaMD: Honored to moderate this very interesting #genetherapy panel…


RT @ThomasCiullaMD: Honored to moderate this very interesting #genetherapy panel discussion, now available via podcast…
OIS Podcast Episo…


Source by Thomas Ciulla, MD, MBA

Return to main website.

Just published: Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene …

Just published: Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases #eyes #retina #macula #GeneTherapy #AMD #diabeticretinopathy #suprachoroidal https://t.co/Hkp7oE1XLp via @MDPIOpenAccess Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ThomasCiullaMD: Recently published: Host immune responses after suprachoroid…

RT @ThomasCiullaMD: Recently published: Host immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes. https://t.co/ Source by Thomas Ciulla, MD, MBA Return to main website.

Honored to moderate this very interesting #genetherapy panel discussion, now ava…


Honored to moderate this very interesting #genetherapy panel discussion, now available via podcast…
OIS Podcast Episode #269: KOLs Speak Out on the Future of Gene Therapy https://t.co/nXMnR91Btg via @YouTube


Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @ophthopedia: Ophthopedia Update: Suprachoroidal CLS-TA for non-infectious uv…

RT @ophthopedia: Ophthopedia Update: Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA) https://t.co/EY Source by Thomas Ciulla, MD, MBA Return to main website.